

20. **Dautzenberg B**, Piperno D, Diot P, *et al*. Clarithromycin in the treatment of *Mycobacterium avium* lung infections in patients without AIDS. Clarithromycin Study Group of France. *Chest* 1995;**107**:1035–40.
21. **Griffith DE**, Brown BA, Girard WM, *et al*. Azithromycin activity against *Mycobacterium avium* complex lung disease in patients who were not infected with human immunodeficiency virus. *Clin Infect Dis* 1996;**23**:983–9.
22. **Huang JH**, Kao PN, Adi V, *et al*. *Mycobacterium avium*-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. *Chest* 1999;**115**:1033–40.
23. **Reich JM**, Johnson RE. *Mycobacterium avium* complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. *Chest* 1992;**101**:1605–9.
24. **Wallace RJ Jr**, Brown BA, Griffith DE, *et al*. Initial clarithromycin monotherapy for *Mycobacterium avium*-intracellulare complex lung disease. *Am J Respir Crit Care Med* 1994;**149**:1335–41.
25. **Tsukamura M**. Diagnosis of disease caused by *Mycobacterium avium* complex. *Chest* 1991;**99**:667–9.
26. **Maekura R**, Okuda Y, Hirotani A, *et al*. Clinical and prognostic importance of serotyping *Mycobacterium avium*-*Mycobacterium intracellulare* complex isolates in human immunodeficiency virus-negative patients. *J Clin Microbiol* 2005;**43**:3150–8.
27. **Kumar S**, Bose M, Isa M. Genotype analysis of human *Mycobacterium avium* isolates from India. *Indian J Med Res* 2006;**123**:139–44.
28. **Singh AV**, Singh SV, Makharia GK, *et al*. Presence and characterization of *Mycobacterium avium* subspecies paratuberculosis from clinical and suspected cases of Crohn's disease and in the healthy human population in India. *Int J Infect Dis* 2008;**12**:190–7.
29. **Wojtasik A**, Augustynowicz-Kopec E, Zwolska Z, *et al*. Genotyping of *Mycobacterium avium*-intracellulare complex based on trinucleotide repeat sequences (TRS) presence in mycobacteria genomes. *J Biotechnol* 2007;**131**:S3–4.
30. **Hanekom M**, van der Spuy GD, Gey van Pittius NC, *et al*. Discordance between mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing and IS6110 restriction fragment length polymorphism genotyping for analysis of *Mycobacterium tuberculosis* Beijing strains in a setting of high incidence of tuberculosis. *J Clin Microbiol* 2008;**46**:3338–45.

## Lung alert

### Cetuximab: a new hope for advanced NSCLC

Advanced (stage IIIb/IV) non-small cell lung cancers (NSCLCs) are associated with poor survival on current chemotherapy regimes. Epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors are second-line treatment options. This is the first study to investigate a monoclonal antibody against the EGFR cetuximab as a potential first-line treatment option.

In this multinational open-label study across 155 centres, 1125 chemotherapy-naïve patients with advanced NSCLC and immunohistochemical evidence of EGFR expression were randomly assigned to chemotherapy with cetuximab or chemotherapy alone. Patients previously treated with monoclonal antibodies or EGFR-targeting drugs were excluded. The primary outcome was overall survival. Secondary outcomes included progression-free survival, tumour response rate, safety and quality of life analyses.

On an intention-to-treat analysis, cetuximab therapy was associated with greater median survival than chemotherapy alone (11.3 vs.10.1 months), greater tumour response rates and a longer time to treatment failure. These findings were independent of histological subtype and other factors known to affect prognosis. No differences were reported between progression-free survival, quality of life outcomes or treatment-related deaths. Infusion reactions with cetuximab were rare.

The authors conclude that combination chemotherapy with cetuximab is a useful first-line therapy for advanced NSCLC. However, changes in symptom score and optimum duration of cetuximab treatment were not assessed. Unfortunately, it is likely that the benefit in overall survival compared with the cost of cetuximab treatment will be an issue in cetuximab becoming a first-line treatment option.

- ▶ Pirker R, Pereira JR, Szczesna A, *et al* and the FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. *Lancet* 2009;**373**:1525–31.

#### S Karmali

**Correspondence to:** S Karmali, Medical Student, University College London, London, UK; s.karmali@ucl.ac.uk

**Provenance and peer review:** Not commissioned; not externally peer reviewed.

*Thorax* 2009;**64**:907. doi:10.1136/thx.2009.121012